Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis

NCT03724929 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Saint Etienne as lead sponsor.

NCT NCT03724929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03724929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Lead sponsor
Centre Hospitalier Universitaire de Saint Etienne
Phase
Not applicable
Overall status
Terminated
Start date
March 4, 2019
Completion date
June 28, 2022
Enrollment
67 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis